Detailed Abstract
[E-poster - Biliary & Pancreas (Pancreas Disease/Surgery)]
[EP 239] The Impact of Lymphangiography for Treatment Duration of Chyle Leak after Pancreatic Surgery
Norihiro ISHII 1, Norifumi HARIMOTO 1, Ryosuke FUKUSHIMA 1, Takayuki OKUYAMA 1, Takaomi SEKI 1, Kei HAGIWARA 1, Kouki HOSHINO 1, Shunsuke KAWAI 1, Mariko TSUKAGOSHI 1, Takamichi IGARASHI 1, Kenichiro ARAKI 1, Ken SHIRABE 1
1 Division of Hepatobiliary And Pancreatic Surgery, Department of General Surgical Science, Gunma University, JAPAN
Background : Chyle leak (CL) is a common complication of pancreatic surgery, and its postoperative incidence has been reported to be 1.3%–16.3%. Lymphangiography is a therapeutic option for CL in case of failure of conservative treatment. This study aimed to investigate the risk factors of CL, and the effect of lymphangiography on the healing time of CL.
Methods : We retrospectively evaluated 283 patients who underwent pancreatic resections between January 2016 and June 2022. The risk factors for CL were analyzed, and the treatment period were evaluated according to whether lymphangiography had been performed.
Results : CL occurred in 29 patients (10.2%), and lymphangiography was performed in 6 of those cases. The univariate analysis revealed that older age, malignant disease, high number of harvested lymph nodes, and high output drain fluid volume on POD2 were risk factors for CL, while the multivariate analysis identified malignant disease, number of harvested lymph nodes, and drain fluid volume on POD2 (P=0.0318, P=0.0146, and P=0.0047, respectively) as independent risk factors for CL. Lymphangiography was significantly associated with the cumulative healing rate of the CL (P=0.0302)), and patients who underwent lymphangiography had a significantly shorter treatment period (P=0.0236). No lymphangiography-related adverse events were observed.
Conclusions : Lymphangiography is a feasible and safe treatment for CL. The treatment period for CL after pancreatic surgery was significantly shorter in the patients who underwent lymphangiography than in those who did not. Our results suggest that lymphangiography may contribute to early improvement of persistent CL.
Methods : We retrospectively evaluated 283 patients who underwent pancreatic resections between January 2016 and June 2022. The risk factors for CL were analyzed, and the treatment period were evaluated according to whether lymphangiography had been performed.
Results : CL occurred in 29 patients (10.2%), and lymphangiography was performed in 6 of those cases. The univariate analysis revealed that older age, malignant disease, high number of harvested lymph nodes, and high output drain fluid volume on POD2 were risk factors for CL, while the multivariate analysis identified malignant disease, number of harvested lymph nodes, and drain fluid volume on POD2 (P=0.0318, P=0.0146, and P=0.0047, respectively) as independent risk factors for CL. Lymphangiography was significantly associated with the cumulative healing rate of the CL (P=0.0302)), and patients who underwent lymphangiography had a significantly shorter treatment period (P=0.0236). No lymphangiography-related adverse events were observed.
Conclusions : Lymphangiography is a feasible and safe treatment for CL. The treatment period for CL after pancreatic surgery was significantly shorter in the patients who underwent lymphangiography than in those who did not. Our results suggest that lymphangiography may contribute to early improvement of persistent CL.
SESSION
E-poster
E-Session 03/21 ALL DAY